ENG and soft tissue sarcoma: Notably, a CD105 therapeutic antibody (TRC105) is already available and was well tolerated upon phase 1 and 2 clinical evaluation in patients with soft tissue sarcoma, hepatocellular and urothelial carcinoma40–42.